Corvus Pharmaceuticals Files 8-K on Financials
Ticker: CRVS · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Corvus Pharma dropped an 8-K detailing its financials - check it for the latest numbers.
AI Summary
Corvus Pharmaceuticals, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 863 Mitten Road, Suite 102, Burlingame, California.
Why It Matters
This 8-K filing provides an update on Corvus Pharmaceuticals' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Registrant
- March 19, 2024 (date) — Date of Report
- 863 Mitten Road, Suite 102, Burlingame, California (location) — Principal executive offices
FAQ
What specific items are included in the financial statements and exhibits filed with this 8-K?
The filing states that 'Financial Statements and Exhibits' are included, but does not list the specific contents within this summary.
What is the Commission File Number for Corvus Pharmaceuticals, Inc.?
The Commission File Number for Corvus Pharmaceuticals, Inc. is 001-37719.
When is Corvus Pharmaceuticals, Inc.'s fiscal year end?
Corvus Pharmaceuticals, Inc.'s fiscal year ends on December 31.
What is the Standard Industrial Classification code for Corvus Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Corvus Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the IRS Employer Identification Number for Corvus Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Corvus Pharmaceuticals, Inc. is 46-4670809.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-19 16:02:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market I
Filing Documents
- f8k_031924.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 69KB
- fig1.jpg (GRAPHIC) — 86KB
- fig2.jpg (GRAPHIC) — 113KB
- 0001171843-24-001454.txt ( ) — 545KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_031924_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 19, 2024, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2023 and its financial position as of December 31, 2023, and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release of Corvus Pharmaceuticals, Inc. dated March 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Corvus Pharmaceuticals, Inc. Date: March 19, 2024 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer